Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.00 Average PT from Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has received an average rating of “Buy” from the seven ratings firms that are covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $43.00.

A number of equities research analysts recently commented on BCAX shares. Morgan Stanley initiated coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price objective for the company. TD Cowen assumed coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating on the stock. HC Wainwright initiated coverage on Bicara Therapeutics in a report on Friday, December 6th. They set a “buy” rating and a $42.00 price objective for the company. Cantor Fitzgerald initiated coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating on the stock. Finally, Rodman & Renshaw began coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating and a $48.00 price target for the company.

Bicara Therapeutics Trading Down 4.4 %

Shares of BCAX opened at $18.27 on Thursday. The stock has a fifty day moving average price of $20.65. Bicara Therapeutics has a one year low of $16.01 and a one year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, research analysts expect that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BCAX. RA Capital Management L.P. bought a new stake in shares of Bicara Therapeutics during the 3rd quarter worth approximately $177,169,000. FMR LLC acquired a new stake in Bicara Therapeutics in the third quarter valued at $57,913,000. Braidwell LP acquired a new stake in Bicara Therapeutics in the third quarter valued at $42,219,000. Janus Henderson Group PLC bought a new position in shares of Bicara Therapeutics in the 3rd quarter valued at about $30,329,000. Finally, Baker BROS. Advisors LP acquired a new position in shares of Bicara Therapeutics during the 3rd quarter worth about $21,225,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.